101 completed, 31 recruiting, 23 unknown, 22 terminated. 220 Phase 1, 92 Phase 2.
Follow Motor Neuron Disease: new trials by email Literature Review of Motor Neuron Disease trials Research Report on Motor Neuron Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN Tetramethylpyrazine nitrone (TBN) tablet / Placebo - Healthy | Phase 1 | Not yet recruiting | Guangzhou Magpie Pharmaceuticals Co., Ltd. | 16 | 2028-09-01 | 2026-09-11 |
| Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS) B cell infusion - ALS - Amyotrophic Lateral Sclerosis | Phase 1 | Not yet recruiting | Mark Poznansky | 10 | 2027-09-01 | 2026-09-24 |
| Safety Study of XT-150 in Participants With ALS XT-150 - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 | Not yet recruiting | Xalud Therapeutics, Inc. | 8 | 2027-03-01 | 2026-07-29 |
| A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS) NI112, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 | Not yet recruiting | Sachi Bioworks Inc. | 40 | 2027-01-22 | 2026-10-30 |
| Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS) Q-Cells - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | Q Therapeutics, Inc. | 30 | 2026-12-01 | 2026-07-08 |
| Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS nL-TARDB-002 - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Enrolling by invitation | n-Lorem Foundation | 1 | 2026-12-01 | 2026-07-14 |
| A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS). LY3873862, CYP450 Drug Cocktail, Placebo - Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System | Phase 1 | Not yet recruiting | Eli Lilly and Company | 32 | 2026-11-01 | 2026-10-20 |
| A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) BIIB147, Placebo - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Biogen | 69 | 2026-10-07 | 2026-10-26 |
| Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS β-hydroxy-β-methylbutyrate (HMB) - Amyotrophic Lateral Sclerosis ALS | Phase 1 | Not yet recruiting | Duke University | 100 | 2026-10-01 | 2026-09-08 |
| Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS) Orelabrutinib - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 | Not yet recruiting | Liu Qing | 12 | 2026-10-01 | 2026-10-15 |
| FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS TRCN-1023, Placebo - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Trace Neuroscience, Inc. | 30 | 2026-08-20 | 2026-10-14 |
| Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis. SonoCloud-4 (SC4) device - Amyotrophic Lateral Sclerosis, Charcot Disease | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 23 | 2026-07-15 | 2026-08-10 |
| A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I SKG0201 Injection - Spinal Muscular Atrophy 1 | Phase 1 / Phase 2 | Recruiting | Lanyue Biotech (Hangzhou) Co., Ltd. | 11 | 2026-07-15 | 2026-10-14 |
| TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis TP04HN106, Saline - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Talengen Institute of Life Sciences, Shenzhen, P.R. China. | 60 | 2026-06-04 | 2026-10-02 |
| A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis LY4256984 - Amyotrophic Lateral Sclerosis | Phase 1 | Recruiting | Eli Lilly and Company | 32 | 2026-05-14 | 2026-09-22 |
| A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) LY4256984 - Amyotrophic Lateral Sclerosis | Phase 1 | Recruiting | Eli Lilly and Company | 32 | 2026-05-14 | 2026-09-22 |
| A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis LTX-002, Placebo (aCSF) - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Leal Therapeutics, Inc | 56 | 2026-04-29 | 2026-08-18 |
| A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients PLL001 or placebo daily subcutaneous injections - Amyotrophic Lateral Sclerosis, ALS | Phase 1 / Phase 2 | Not yet recruiting | PLL TX AUSTRALIA PTY LTD | 153 | 2026-04-08 | 2026-03-19 |
| Safety and Efficacy of Intrathecal NTF001 Injection in ALS NTF001 Injection - ALS - Amyotrophic Lateral Sclerosis, ALS (Amyotrophic Lateral Sclerosis) | Phase 1 | Active not recruiting | Ruijin Hospital | 12 | 2026-04-01 | 2026-06-01 |
| A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. NB-4746 High dose, NB-4746 Low dose, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Recruiting | Nura Bio | 80 | 2026-03-04 | 2026-09-17 |
Showing 20 of 220. Sign in to see all of them.
Amyotrophic Lateral Sclerosis (172) · Muscular Atrophy, Spinal (24) · Bulbo-Spinal Atrophy, X-Linked (15) · Spinal Muscular Atrophies of Childhood (10) · Neurodegenerative Diseases (8) · Prostatic Neoplasms (7) · Neuromuscular Diseases (5) · Parkinson Disease (4) · Alzheimer Disease (3) · Amyotrophic lateral sclerosis 1 (2) · Central Nervous System Diseases (2) · Fasciculation (2) · Frontotemporal Dementia With Motor Neuron Disease (2) · Lewy Body Disease (2)
Nervous System Diseases (218) · Spinal Cord Diseases (217) · Central Nervous System Diseases (215) · Neuromuscular Diseases (215) · Neurodegenerative Diseases (212) · Metabolic Diseases (172) · Nutritional and Metabolic Diseases (172) · Proteostasis Deficiencies (172) · TDP-43 Proteinopathies (172) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (25) · Genetic Diseases, Inborn (25) · Heredodegenerative Disorders, Nervous System (25) · Muscular Atrophy, Spinal (22) · Genetic Diseases, X-Linked (15)
nusinersen (5) · 4-phenylbutyric acid (4) · Dexpramipexole (4) · Risdiplam (4) · Copper (3) · Riluzole (3) · Hydroxyurea (2) · Injections, Spinal (2) · Itraconazole (2) · Laminectomy (2) · Midazolam (2) · Prednisolone (2) · Prednisone (2) · Rabeprazole (2) · Sodium Chloride (2)
Biogen (11) · n-Lorem Foundation (7) · Hoffmann-La Roche (5) · Knopp Biosciences (5) · Eli Lilly and Company (4) · Newron Sweden AB (4) · Royan Institute (4) · Sanofi (4) · GeneCradle Inc (3) · Hanyang University Seoul Hospital (3) · National Institute of Neurological Disorders and Stroke (NINDS) (3) · Phoenix Neurological Associates, LTD (3) · University of Utah (3) · Accutar Biotechnology Inc (2) · Amylyx Pharmaceuticals Inc. (2)
United States (110) · Canada (24) · Netherlands (24) · China (19) · United Kingdom (16) · Germany (15) · Belgium (13) · Australia (12) · Italy (10) · South Korea (10) · Spain (10) · France (8) · Poland (8) · Iran (6) · Japan (6)
Hamid Gourabi, PhD (4) · Nasser Aghdami, MD,PhD (4) · Dominic Rowe, MD (3) · Todd D Levine, MD (3) · Diego Cadavid, MD (2) · Dr Ching H. Wang (2) · Richard Bedlack, MD, PhD (2) · Seyed Masoud Nabavi, MD (2) · Wojciech Maksymowicz, MD, Prof. (2)
PMID 31420846, PMID 22415951, PMID 23463272, PMID 26823478, PMID 30124008, PMID 37148485, PMID 11050032, PMID 15084121, PMID 17978354, PMID 18270879, PMID 19440247, PMID 22415942, PMID 22565043, PMID 23300829, PMID 23541756, PMID 24820540, PMID 24841795, PMID 25324884, PMID 25889343, PMID 25934946, PMID 26746183, PMID 26751635, PMID 27515308, PMID 27581221, PMID 27938483, PMID 28674982, PMID 29091557, PMID 30048006, PMID 30158984, PMID 30531015, PMID 30548438, PMID 30879249, PMID 31019106, PMID 31272829, PMID 31277975, PMID 31446511, PMID 31629403, PMID 31797084, PMID 32265627, PMID 32878613, PMID 33031745, PMID 34016561, PMID 34333820, PMID 34383289, PMID 34558001, PMID 34678870, PMID 34716445, PMID 34719198, PMID 35110415, PMID 35154390
2017 (5), 2023 (5), 2025 (5), N01NS42361 (2), 2014 (1), 2015 (1), 2019 (1), R01HD054599 (1), R21HD054697 (1)